Elanco Animal Health (NYSE:ELAN) Updates FY25 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.80-$0.86 for the period, compared to the consensus estimate of $0.89. The company issued revenue guidance of $4.445-$4.510 billion, compared to the consensus revenue estimate of $4.52 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ELAN. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday. Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price objective on the stock. Finally, Stifel Nicolaus reduced their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $15.83.

Elanco Animal Health Stock Up 2.4 %

Shares of NYSE:ELAN traded up $0.27 during trading on Friday, reaching $11.19. 6,902,175 shares of the company traded hands, compared to its average volume of 4,960,017. Elanco Animal Health has a 1-year low of $10.20 and a 1-year high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a market cap of $5.53 billion, a P/E ratio of 27.96, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The firm has a fifty day simple moving average of $11.71 and a 200 day simple moving average of $13.03.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business posted $0.08 EPS. Elanco Animal Health's revenue for the quarter was down 1.4% on a year-over-year basis. Analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.